Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
06/2010
06/01/2010CA2440680C Steroids as agonists for fxr
06/01/2010CA2426625C Combination of fenofibrate and coenzyme q10 for the treatment of endothelial dysfunction
06/01/2010CA2400626C Estrogen receptor modulators
06/01/2010CA2352524C Aromatic heterocyclic compounds as antiinflammatory agents
05/2010
05/27/2010WO2010060041A2 Phenylalanine amide inhibitors of atp-sensitive potassium channels
05/27/2010WO2010059859A1 Tgr5 modulators and methods of use thereof
05/27/2010WO2010059662A2 Constitutive androstane receptor (car) as a therapeutic target for obesity and type two diabetes
05/27/2010WO2010059639A2 Hydroxyadamantyl inhibitors of dipeptidylpeptidase iv
05/27/2010WO2010059627A1 Polar quinazolines as liver x receptors ( lxrs ) modulators
05/27/2010WO2010059602A2 Inhibitors of diacylglycerol acyltransferase
05/27/2010WO2010059385A1 Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidne derivatives useful as gdir agonists
05/27/2010WO2010058858A1 Novel pyrazole-3-carboxamide derivative having 5-ht2b receptor antagonist activity
05/27/2010WO2010058846A1 4,6-diaminonicotinamide compound
05/27/2010WO2010058794A1 Antioxidant
05/27/2010WO2010058517A1 NERVE CELL STIMULATOR COMPRISING IgG AND/OR Fc FRAGMENT OF IgG
05/27/2010WO2010058512A1 Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives
05/27/2010WO2010058318A1 1-oxa-8-azaspiro [4, 5 ] decane- 8 -carboxamide compounds as faah inhibitors
05/27/2010WO2010057877A1 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
05/27/2010WO2010057804A1 Fat emulsion for artificially feeding seriously ill intensive care patients
05/27/2010WO2010057774A1 Site-specific monoconjugated insulinotropic glp-1 peptides
05/27/2010WO2010017055A3 Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
05/27/2010WO2010013978A3 Composition for prevention or treatment of hyperlipidemia, fatty liver or obesity
05/27/2010WO2010011926A3 A novel betaine cocrystal of epalrestat
05/27/2010WO2009140624A3 Glucokinase activators
05/27/2010US20100130615 Sulfonylurea inhibitors of atp-sensitive potassium channels
05/27/2010US20100130608 Compositions and methods for reducing triglyceride levels
05/27/2010US20100130559 Novel phenyl-isoxazol-3-ol derivative
05/27/2010US20100130557 Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions
05/27/2010US20100130546 Quinolone compound and pharmaceutical composition
05/27/2010US20100130542 Composition Comprising a Combination of Omeprazole and Lansoprazole, and a Buffering Agent, and Methods of Using Same
05/27/2010US20100130521 Method of treatment using fused aromatic compounds having anti-diabetic activity
05/27/2010US20100130512 Fused-ring heterocycle opioids
05/27/2010US20100130511 Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
05/27/2010US20100130510 Compounds for inflammation and immune-related uses
05/27/2010US20100130504 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
05/27/2010US20100130501 Novel 3-amino-pyrrolo[3,4-c]pyrazole-5(1h, 4h, 6h) carbaldehyde derivatives
05/27/2010US20100130496 Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase
05/27/2010US20100130484 Novel bicyclic sulfonamide derivatives which are l-cpt1 inhibitors
05/27/2010US20100130483 Novel diazabicyclic aryl derivatives
05/27/2010US20100130477 Spirocyclobutyl Piperidine Derivatives
05/27/2010US20100130476 Compounds that induce pancreatic beta-cell expansion
05/27/2010US20100130472 Bile acid recycling inhibitors for treatment of obesity and diabetes
05/27/2010US20100130447 Inhibitors of kinase activity
05/27/2010US20100130446 Nitrogen-containing five-membered heterocyclic compound
05/27/2010US20100130435 Utilization of the function of rare sugar as promoter for the migration of glucokinase from nucleus to cytoplasm
05/27/2010US20100130432 Non-Natural Amino Acids and Neurotensin Analogues Thereof
05/27/2010US20100130426 Compositions containing satiogens and methods of use
05/27/2010US20100130424 Crhr2 peptide agonists and uses thereof
05/27/2010US20100130422 Use of cocoa extract
05/27/2010US20100130412 Compositions to prevent and treat type-1 diabetes
05/27/2010US20100130404 Biomarkers for cardiodiabetes
05/27/2010US20100130403 Biomarkers for insulin efficacy
05/27/2010US20100130402 Biomarkers for insulin resistance and beta-cell dysfunction
05/27/2010US20100130401 Protein hydrolysate and plant sterol containing composition for improving serum lipid profile and preventing atheroscleroris
05/27/2010US20100129478 Plant Extracts and Methods and Uses Therefore
05/27/2010US20100129459 biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
05/27/2010US20100129453 Emulsions comprising rubber arabicum
05/27/2010US20100129447 Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
05/27/2010US20100129365 Treatment of inflammation using bst2 inhibitor
05/27/2010US20100129351 Compositions and Methods for Altering Pancreas or Liver Function
05/27/2010US20100129344 Medical uses and therapies based upon the action of azurocidin on igfbp-1
05/27/2010US20100129343 Use Of A Compound For Enhancing The Expression Of Membrane Proteins On The Cell Surface
05/27/2010US20100129311 Phenylalanine amide inhibitors of atp-sensitive potassium channels
05/27/2010DE102008059133A1 Difluorphenyl-diacylhydrazid-derivate Difluorophenyl diacylhydrazide derivatives
05/27/2010CA2744135A1 Tgr5 modulators and methods of use thereof
05/27/2010CA2744012A1 Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives
05/27/2010CA2743723A1 Inhibitors of diacylglycerol acyltransferase
05/27/2010CA2743609A1 Inhibitors of diacylglycerol acyltransferase
05/27/2010CA2742946A1 Antioxidant
05/27/2010CA2742023A1 Polar quinazolines as liver x receptors ( lxrs ) modulators
05/27/2010CA2741839A1 1-oxa-8-azaspiro [4,5] decane-8-carboxamide compounds as faah inhibitors
05/27/2010CA2741511A1 Novel pyrazole-3-carboxamide derivative having 5-ht2b receptor antagonist activity
05/27/2010CA2739390A1 Fat emulsion for artificially feeding seriously ill intensive care patients
05/26/2010EP2189475A2 Fibroblast growth factor-like polypeptides
05/26/2010EP2189459A1 Stable crystalline salt of 5-methyll-(6S)-tetrahydrofolic acid
05/26/2010EP2189458A1 Aryl amide compound as an acetyl coenzyme A carboxylase inhibitor
05/26/2010EP2189449A1 Aminopyrazole amide derivative
05/26/2010EP2189448A1 Processes for the Separation of 3-Benzazepine Racemates
05/26/2010EP2189445A1 Five-membered heterocyclic compound
05/26/2010EP2189439A2 CaSR antagonist
05/26/2010EP2189163A1 A composition for treatment of diabetes mellitus and a preparation and an use thereof
05/26/2010EP2189160A1 Composition comprising sesamin component and vitamin b1 component
05/26/2010EP2188299A2 A method for treating diabetes
05/26/2010EP2188286A1 Process for the preparation of pyrido [2, 1-a]isoquinoline derivatives and polymorphic froms thereof
05/26/2010EP2188273A2 Novel substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
05/26/2010EP2188263A1 Benzimidazole derivatives used as fxr agonists
05/26/2010EP2188253A2 Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof
05/26/2010EP2188015A2 Use of salusin beta alone or in combination with octreotide as a therapeutic agent
05/26/2010EP2187956A2 Use of a laminin peptide as a therapeutic agent
05/26/2010EP2187952A1 Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents
05/26/2010EP2187950A1 Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent
05/26/2010EP2187949A2 Use of glp-1 as a therapeutic agent
05/26/2010EP2187948A2 Use of a peptide as a therapeutic agent
05/26/2010EP2187947A2 Use of calcitonin as anti-angiogenic agent
05/26/2010EP2187946A1 Use of a peptide as a therapeutic agent
05/26/2010EP2187934A1 Use of fertirelin and delta-endorphin as therapeutic agents
05/26/2010EP2187933A1 Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
05/26/2010EP2187931A2 Use of a combination of cart peptides as a therapeutic agent
05/26/2010EP2187930A2 Trap-14 as a therapeutic agent
05/26/2010EP2187926A1 Prevention of type 1 diabetes by administration of gliadin
1 ... 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 ... 1298